12:00 AM
May 25, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Velcade bortezomib: Phase II data

Data from the Phase II VERTICAL trial in 15 evaluable patients receiving Velcade plus Treanda bendamustine and Rituxan rituximab showed that there were 2 cases of dose-limiting toxicities: severe rash in the 70 mg/m 2 Treanda arm and grade 3 thrombocytopenia in the 90 mg/m 2 Treanda arm. Hematologic adverse events were manageable and included...

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >